^
Association details:
| Biomarker: | PD-L1 expression + CD47 expression |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | NI-2901 (PD-L1 inhibitor, CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2951 / 29 - NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade
Published date:
03/15/2023
Excerpt:
In immunocompetent huCD47/huSIRPα-transgenic mice engrafted with MC38 cells engineered to express human PD-L1 and CD47, NI-2901 displayed significant anti-tumor activity….Also, NI-2901 demonstrated significant antitumor activity in vivo and is therefore expected to show improved clinical efficacy over PD-1/PD-L1 blockade alone.
